Miura R, Ono A, Nakahara H, Shirane Y, et al. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol 2024 Dec 9. doi: 10.1007/s00535-024-02185.
PMID: 39652104